富马酸替诺福韦二吡呋酯治疗慢性乙型肝炎的短期疗效分析

Analysis of the short-term efficacy of tenofovir dipivoxil fumarate in the treatment of chronic hepatitis B

目的探讨富马酸替诺福韦二吡呋酯(TDF)治疗慢性乙型肝炎(CHB)的短期疗效.方法100例慢性乙型肝炎患者,随机分为对照组和研究组,每组50例.对照组患者采用恩替卡韦治疗,研究组患者在对照组基础上联合富马酸替诺福韦二吡呋酯治疗.比较两组患者治疗前后肝功能、乙型肝炎病毒(HBV)DNA,乙型肝炎病毒e抗原(HBeAg)转阴、丙氨酸转氨酶复常以及临床有效情况,不良反应发生情况.结果治疗后,两组患者丙氨酸转氨酶、天冬氨酸转氨酶、总胆红素、乙型肝炎病毒DNA水平均低于本组治疗前,且研究组丙氨酸转氨酶(45.30±20.45)U/L、天冬氨酸转氨酶(24.95±9.85)U/L、总胆红素(13.65±4.85)μmol/L、乙型肝炎病毒DNA(85.45±5.15)U/ml均低于对照组的(58.30±20.65)U/L、(40.03±10.03)U/L、(16.30±4.85)μmol/L、(108.30±6.28)U/ml,差异具有统计学意义(P<0.05).两组患者HBeAg转阴率、丙氨酸转氨酶复常率以及临床有效率比较差异无统计学意义(P>0.05).研究组患者不良反应发生率为4.00%,明显低于对照组的18.00%,差异具有统计学意义(P<0.05).结论慢性乙型肝炎应用富马酸替诺福韦二吡呋酯治疗的短期疗效确切.

Objective To discuss the short-term efficacy of tenofovir dipivoxil fumarate(TDF)in the treatment of chronic hepatitis B(CHB).Methods A total of 100 chronic hepatitis B patients were randomly divided into control group and research group,with 50 cases in each group.The control group was treated by entecavir,and the research group was treated by tenofovir dipivoxil fumarate on the basis of the control group.The liver function and Hepatitis B virus(HBV)DNA before and after treatment,negative conversion of hepatitis B e antigen(HBeAg),normalization of alanine transaminase,clinical efficacy and occurrence of adverse reactions was compared between the two groups.Results After treatment,the alanine aminotransferase,aspartate aminotransferase,total bilirubin,hepatitis B virus DNA in the two groups was lower than those before treatment.The alanine aminotransferase,aspartate aminotransferase,total bilirubin,hepatitis B virus DNA was(45.30±20.45)U/L,(24.95±9.85)U/L,(13.65±4.85)μmol/L and(85.45±5.15)U/ml respectively in the research group,which was lower than(58.30±20.65)U/L,(40.03±10.03)U/L,(16.30±4.85)μmol/L and(108.30±6.28)U/ml in the control group.Their difference was statistically significant(P<0.05).There was no statistically significant difference in negative conversion of HBeAg,normalization rate of alanine transaminase and clinical efficacy in the two groups(P>0.05).The incidence of adverse reactions was 4.00% in the research group,which was obviously lower than 18.00% in the control group,and the difference was statistically significant(P<0.05).Conclusion Tenofovir fumarate dipivoxil shows affirmative short-term efficacy of in the treatment of chronic hepatitis B.